These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Enteric-coated mycophenolate sodium as a corticosteroid-sparing agent for the treatment of autoimmune scleritis.
    Author: Hwang YS, Chen HC, Chen KJ, Lai CC, Yeung L, Yang KJ, Lin KK, Hsiao CH.
    Journal: Cornea; 2011 Mar; 30(3):260-4. PubMed ID: 21099416.
    Abstract:
    PURPOSE: To evaluate enteric-coated mycophenolate sodium (EC-MPS) as a corticosteroid-sparing agent in the treatment of autoimmune scleritis. METHODS: A retrospective, interventional, noncomparative review of EC-MPS use in patients with autoimmune scleritis. RESULTS: Seven eyes of 5 patients (all female; median age: 47 years, range: 20-55 years) with inflammatory scleral disease were treated with EC-MPS. The mean follow-up duration was 16.4 months (range, 12-20 months). EC-MPS was started at 360 mg twice daily. The mean time to treatment success was 1.6 months (range, 1-3 months). The mean prednisolone dosage at the onset of EC-MPS was 24 mg daily (range, 15-30 mg), and this was reduced to 6.5 mg daily (range, 0-10 mg) as inflammation control was achieved. No severe adverse events except for 1 patient with transient knee pain were reported; the incidence of adverse events after using EC-MPS was 1/6.83 person-years. There was no recurrence of scleral inflammation during the follow-up period. CONCLUSIONS: EC-MPS can be used as a corticosteroid-sparing agent to safely suppress inflammatory autoimmune scleritis.
    [Abstract] [Full Text] [Related] [New Search]